Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Solwers Plc issues 58,071 new shares

Solwers Plc Company Release 23.02.2024 at 09.45 a.m. EEST Solwers Plc announced on 29 January 2024 that it is expanding the range of services offered to the industry by acquiring the entire share capital of the Swedish Relitor Engineering AB. Part of the purchase price was agreed to be paid with Solwers Plc’s shares. The total number of shares directed to the sellers is 58,071 shares. The 58,071 new shares have today been registered in the trade register maintained by the Finnish Patent and Registration Office and the total number of shares issued by Solwers Plc increases from 9,946,

Tobii’s intended rights issue fully covered by subscription and guarantee undertakings

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN TOBII AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.Tobii AB (publ) today announces that its intended rights issue of approximately SEK 300 million is fully covered by subscription and guarantee undertakings.

The subscription period in Curasight’s rights issue begins today

Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the “Company" – TICKER: CURAS) new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"), which was resolved by the Board of Directors on 13 February 2024.Summary of the Rights Issue · Each existing share in the Company, as of the record date on 22 February 2024, entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to

Ellos Group AB (publ) interim report January - December 2023

Press release, Borås, 23 February 2024   The interim report for Ellos Group AB (publ) is published today. THE FOURTH QUARTER 2023 • Net sales decreased by 4.7 % to SEK 993.6 (1 042.2) million. Organically, net sales decreased by 4.5 %. • The gross margin increased to 51.8 (49.3) %. • Adjusted EBITA increased to SEK 73.5 (26.5) million. The adjusted EBITA margin increased to 7.4 (2.5) %. • The operating profit/loss increased to SEK 42.3 (-11.6) million. The operating margin increased to 4.3 (-1.1) %. • Cash flow from operating activities amounted to SEK 157.2 (68.6)

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Press Release – Oslo, Norway, February 23, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that that the international multicenter Phase III clinical study of Cevira[®] (APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), has been selected for late breaking oral presentation at the 2024 SGO Annual Meeting on Women’s Cancer of the Society of Gynecologic Oncology, to be held March 16-18 in San Diego, CA, USA:· Oral presentation:

Heliospectra (publ) Publish the Year-End Report for 2023

(GOTHENBURG, Sweden, Feb 23, 2024, at 08:30 CET)– Heliospectra AB (publ), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its Year-End Report for 2023.Full report is enclosed to this press release and is also uploaded at https://heliospectra.com/investor-relations/financial-reports-documents/reports/. SUMMARY OF REPORT Sales and financial performance October – December 2023 · Order intake during the period amounted to SEK 9,377 (12,677) thousand. · Net sales during the period amounted to SEK 9,908 (9,998) thousand.

Wyld Networks sign an agreement with Staw Agricultura to deploy Wyld Connect for strawberry production in Brazil

Brazilian strawberry producer, Staw Agricultura, will deploy Wyld Network’s sensor to satellite technology to collect soil moisture data from strawberry farms in the south-east of Brazil.The global fresh strawberry market size was valued at US$ 19.1 billion in 2022 and is expected to expand at a CAGR of 6.03% between 2024 and 2031, reaching US$ 27.2 billion by 2031.   Central to this rapid growth is the Brazil strawberry production market exemplified by Staw Agricultura based in the city of Pinhalão in the Brazilian State of Parana. Staw Agricultura utilise new technologies to produce

Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2023

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2023.July - December 2023  · Net sales amounted to SEK 0 (0). ·  Operating profit amounted to SEK 240,145 (237,140). · Profit per average number of shares after tax amounted to 0.01 (0.01) January - December 2023 · Net sales amounted to SEK 0 (0). ·  Operating profit amounted to SEK -3,108,861 (-2,317,061) · Profit per average number of shares after tax amounted to -0.10 (-0.15) The report is published at www.clinescientific.com/financial-reports For more

Valmet’s social responsibility program continues with several area-specific projects around the world

Valmet Oyj’s press release on February 23[rd], 2024 at 9:30 a.m. EETValmet expanded its global social responsibility program with several area-specific local projects promoting science, nature and equal opportunities in 2022. After a year of successful implementation, the program now continues through six local projects. Social responsibility program is part of Valmet’s sustainability agenda implementation. Some of the projects are selected by employee voting, increasing involvement and internal engagement.  In 2024, the program continues with the following projects:  In Asia

Clinical Laserthermia Systems AB publishes Year-end report January – December 2023

Summary of the interim report (relates to the Group) Full year (01/01/2023–12/31/2023) · Net sales totaled SEK 8,273,000 (SEK 6,268,000). · Operating profit/loss totaled SEK –65,933,000 (SEK -67,442,000) · Profit/loss after financial items totaled SEK –80,875,000 (SEK -71,265,000). · Basic and diluted earnings per share totaled SEK -0.12 (SEK -0.85). · The equity ratio at December 31, 2023, was 75,4% (18,6%). The fourth quarter (10/01/2023 – 12/31/2023) · Net sales totaled SEK 4,456,000 (SEK 4,295,000). · Operating profit/loss totaled SEK –20,408,000 (SEK -18,

The subscription period in Elicera Therapeutics’ rights issue of units starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.   Today, February 23, 2024, the subscription period begins in Elicera Therapeutics AB’s (publ) (“Elicera” or the “Company”) rights issue of units consisting of

JM’s subsidiary AB Borätt acquiring building rights for residential development in Sollentuna

AB Borätt has acquired building rights for the development of approximately 220 residential units located in Sollentuna just north of Stockholm. The acquisition amounts to approximately SEK 150m including a paid development contribution. Occupancy and first payment will take place in the first quarter of 2024. Final payment will take place in the second quarter of 2026.The acquisition will be reported within the JM Residential Stockholm business segment in the first quarter of 2024.   The property has a detailed plan that has gained legal force and is judged to allow the development

ARTE COLLECTUM I AB (PUBL) FINANCIAL STATEMENT 2023

PRESS RELEASE23 February 2024, at 08:00 – Stockholm.Arte Collectum I AB (publ)www.artecollectum.comArte Collectum I AB (publ) (the “Fund”) issues a year-end report regarding the period 1 January 2023 to 31 December 2023. · The operating profit amounted to TEUR -695. · The profit after tax amounted to TEUR -365. · The investments in art amounted to TEUR 7,021. · The value of the portfolio amounted to TEUR 15,157 as per 31 December 2023. · The net asset value (NAV) per unit in the Fund amounted to EUR 9,403 corresponding to 94.03 per cent, with a theoretical NAV which

Closing of Share for Debt Settlement

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES CLOSING OF SHARE FOR DEBT SETTLEMENT   VANCOUVER, BC – (23 February 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE:MYIG) (FSE: 0NFA), (OTC: MYCOF) (the “Company” or “Mydecine”) announces that it has closed a debt settlement (the “Debt Settlement”) to partially settle outstanding debts owed to a creditor (the “Creditor”) for legal services rendered. Pursuant to the Debt Settlement, the Company issued an aggregate of 2,618,543 common shares (“Shares”) at a deemed price of $0.02 per Share, based on a 20-day VWAP (the “Share

Safello publishes Year-End Report 2023 and presents positive EBITDA

Stockholm, 23 February 2024 | Today, Safello Group AB (“Safello”) publishes the company’s year-end report (1 October–31 December) 2023. The report is attached hereto and can be found on safello.com/ir . Summary of the fourth quarter (Oct-Dec 2023) · Net turnover increased by 18 % and amounted to SEK 171.2 million (145.2). · Gross profit increased by 17 % and amounted to SEK 9.3 million (8.0).  · Operating profit before depreciation and amortization (EBITDA) amounted to SEK 0.1 million (-2.0). · Operating profit amounted to SEK 2.3

ICA Gruppen publishes annual report 2023

ICA Gruppen’s annual report 2023 is now available at www.icagruppen.se.The annual report, which also includes ICA Gruppen’s sustainability report, is available as a downloadable PDF document. In addition, an annual overview is published providing a broader presentation of ICA Gruppen's operations during the year. Annual report in English: Year in review/Report  Annual report in Swedish: Year in review/Report  For more informationICA Gruppen press service, telephone number: +46 (0)10 422 52 52, e-

Redsense Medical presents at Stora AktiedagarnaStockholm

Stora Aktiedagarna in Stockholm, March 5-7, 2024, is a three-day event organized by Aktiespararna. During theses days, more than 50 large and small companies will be presenting. The event will be held at Birger Jarl Konferens in Stockholm. Redsense Medical CEO Pontus Nobréus will present the company on March 5. The presentation will be held in Swedish. For further information and registration to the event, please visit: https://www.aktiespararna.se/aktiviteter/stora-aktiedagarna-i-stockholm-44839

Notice to attend extraordinary general meeting in Pagero Group AB (publ)

The shareholders in Pagero Group AB (publ), 559189-9173, are hereby summoned to an extraordinary general meeting on Monday 18 March 2024, at 17.00 at the company’s office, Västra Hamngatan 1 in Gothenburg, Sweden.The extraordinary general meeting has been convened following a request from the shareholder Thomson Reuters Finance S.A. ("Thomson Reuters") to determine the number of directors of the Board of Directors, resolve on remuneration to the Board of Directors and to elect new members of the Board of Directors and a new chairman of the Board of Directors. Entitled to participate in

Sivers Semiconductors showcasing the broadest mmWave portfolio on the market at Mobile World Congress 2024

Kista // Sweden// Feb 23, 2024 // Sivers Semiconductors (STO:SIVE)  will showcase its industry-leading mmWave portfolio of 5GmmWave, unlicensed 5G, and satellite communications (SATCOM) products at Mobile World Congress (MWC) 2024 in Barcelona from February 26[th]-29[th].As the premier event for the connectivity industry, MWC attracts tens of thousands of executives, innovators, and policymakers searching for the latest and greatest technological advancements. This year, Sivers will cement its position as the top provider of high-performance mmWave solutions by demonstrating its unmatched

Nightingale Health receives regulatory approval for healthcare use from Health Sciences Authority in Singapore

Press release, 23 February 2024 at 9:00 a.m. (EET) Nightingale Health, a pioneer in health risk detection and preventative health, has received regulatory approval from Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. This first approval covers the analysis of eight common clinically used biomarkers: total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine. Nightingale Health announced in November 2023 a collaboration

Invitation to NYAB Plc's webcast on financial statement release

NYAB PlcINVESTOR NEWS23 February 2024 at 09:00 Invitation to NYAB Plc’s webcast on financial statement release NYAB Plc will publish its financial statement release for 2023 on Wednesday, 28 February 2024. On the same day at 15:00 EET, the company will arrange a webcast in which CEO Johan Larsson and CFO Aku Väliaho will present NYAB’s financial information and significant events for the financial year. The webcast will be held in English. However, participants can ask questions via the event chat room in both Finnish and English. Registration for the webcast can be done at

Year-end report 2023

FOURTH QUARTER (OCTOBER – DECEMBER 2023) · Order intake SEK 317.7 M (514.4) · Net sales SEK 299.6 M (264.4) · Operating profit SEK 44.4 M (20.7) · Profit after tax SEK 31.5 M (14.1) · Earnings per share before/after dilution SEK 0.92 (0.41) · Cash flow SEK 45.5 M (42.8) · Order backlog SEK 1,864.4 M (1,940.1) at the end of the period TWELVE MONTHS (JANUARY – DECEMBER 2023) · Order intake SEK 1,004.2 M (1,218.5) · Net sales SEK 1,022.2 M (843.6) · Operating profit SEK 114.9 M (42.7) · Profit after tax SEK 81.6 M (23.8) · Earnings per share before/

There are no items matching the current filter
There are no more items matching the current filter
Back to top